-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Admilparant in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Admilparant in Idiopathic Pulmonary Fibrosis Drug Details: Admilparant (BMS-986278) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Tipelukast (KCA-757) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Primary Sclerosing Cholangitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Primary Sclerosing Cholangitis Drug Details: Bexotegrast (PLN-74809) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Liver Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Liver Fibrosis Drug Details: Bexotegrast (PLN-74809) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Idiopathic Pulmonary Fibrosis Drug Details: Bexotegrast (PLN-74809) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Idiopathic Pulmonary Fibrosis Drug Details: Tipelukast (KCA-757) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – QR-0561 in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QR-0561 in Idiopathic Pulmonary Fibrosis Drug Details: QR-0561 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Systemic Sclerosis (Scleroderma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fipaxalparant in Systemic Sclerosis (Scleroderma) Drug Details: Fipaxalparant (HZN-825) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMB-053 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AMB-053 in Idiopathic Pulmonary Fibrosis Drug Details:AMB-053 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – QR-0561 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.QR-0561 in Idiopathic Pulmonary Fibrosis Drug Details: QR-0561 is under development for the treatment of idiopathic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Admilparant in Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Admilparant in Pulmonary Fibrosis Drug Details: Admilparant (BMS-986278) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGS-2525 in Bronchiectasis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MGS-2525 in Bronchiectasis Drug Details: MGS-2525 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Tipelukast (KCA-757) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipelukast in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tipelukast in Type 2 Diabetes Drug Details: Tipelukast (KCA-757) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ISM-001 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ISM-001 in Idiopathic Pulmonary Fibrosis Drug Details:ISM-001055 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANPA-0073 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANPA-0073 in Idiopathic Pulmonary Fibrosis Drug Details: ANPA-0073 is under development for the treatment of pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANPA-0073 in Pulmonary Arterial Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANPA-0073 in Pulmonary Arterial Hypertension Drug Details: ANPA-0073 is under development for the treatment of pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MGS-2525 in Chronic Obstructive Pulmonary Disease (COPD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MGS-2525 in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: MGS-2525 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AM-1476 in Systemic Sclerosis (Scleroderma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AM-1476 in Systemic Sclerosis (Scleroderma) Drug Details:AM-1476 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pirfenidone in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Pirfenidone in Idiopathic Pulmonary Fibrosis Drug Details:Pirfenidone (GP-101) is under development for the treatment of interstitial...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.